Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Buch, M. H.
Right arrow Articles by Emery, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buch, M. H.
Right arrow Articles by Emery, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 243-244
British Society for Rheumatology 2004; all rights reserved

Letter to the Editor

Long-term treatment of rheumatoid arthritis with tumour necrosis factor {alpha} blockade: outcome of ceasing and restarting biologicals

M. H. Buch, H. Marzo-Ortega, S. J. Bingham and P. Emery

Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK

Correspondence to: P. Emery, Academic Unit of Musculoskeletal Disease, 1st Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. E-mail: p.emery@leeds.ac.uk

The first 10% of the full text of this article appears below.

SIR, Infliximab, a chimeric monoclonal antibody, has demonstrated effective suppression of disease and prevention of the progression of structural damage in rheumatoid arthritis (RA) in its phase III randomized study (ATTRACT study) [1, 2]. Two anti-tumour-necrosis factor {alpha} (TNF-{alpha}) drugs, infliximab and etanercept, have recently been approved by the National Institute of Clinical Excellence [3].

With a large number of patients at a single centre for the ATTRACT study [1], the follow-up . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
M. H. Buch, D. Bryer, S. Lindsay, B. Rees-Evans, A. Fairclough, and P. Emery
Shortening infusion times for infliximab administration
Rheumatology, April 1, 2006; 45(4): 485 - 486.
[Full Text] [PDF]